Want to see SE:ERMA full AI Analyst Report?
Enorama Pharma AB (ERMA) Stock Statistics & Valuation Metrics
Total Valuation
Enorama Pharma AB has a market cap or net worth of SEK 58.93M. The enterprise value is SEK 18.04M.
- Market Cap
- SEK 58.93M
- Enterprise Value
- SEK 18.04M
Share Statistics
Enorama Pharma AB has 74,588,684 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 74,588,684
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Enorama Pharma AB’s return on equity (ROE) is 3.20 and return on invested capital (ROIC) is 264.89%.
- Return on Equity (ROE)
- 3.20
- Return on Assets (ROA)
- -9.09
- Return on Invested Capital (ROIC)
- 264.89%
- Return on Capital Employed (ROCE)
- 2.65
- Revenue Per Employee
- 684.75K
- Profits Per Employee
- -18.78M
- Employee Count
- 4
- Asset Turnover
- 0.33
- Inventory Turnover
- 36.87
Valuation Ratios
The current PE Ratio of Enorama Pharma AB is -0.93. Enorama Pharma AB’s PEG ratio is -0.03.
- PE Ratio
- -0.93
- PS Ratio
- 38.63
- PB Ratio
- -1.11
- Price to FCF
- -1.05
- Price to Operating Cash Flow
- -1.05
- PEG Ratio
- -0.03
Income Statement
In the last 12 months, Enorama Pharma AB had revenue of 2.74M and earned -75.14M in profits. Earnings per share was -1.08.
- Revenue
- 2.74M
- Gross Profit
- -61.78M
- Operating Income
- -62.12M
- Pretax Income
- -75.14M
- Net Income
- -75.14M
- EBITDA
- -61.65M
- Earnings Per Share (EPS)
- -1.08
Cash Flow
In the last 12 months, operating cash flow was -53.05M and capital expenditures 14.79M, giving a free cash flow of -53.05M billion.
- Operating Cash Flow
- -53.05M
- Free Cash Flow
- -53.05M
- Free Cash Flow per Share
- -0.71
Dividends & Yields
Enorama Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -94.83%
- Earnings Yield
- -106.68%
Stock Price Statistics
- Beta
- 0.99
- 52-Week Price Change
- -71.58%
- 50-Day Moving Average
- 0.77
- 200-Day Moving Average
- 0.57
- Relative Strength Index (RSI)
- 47.25
- Average Volume (3m)
- 232.45K
Important Dates
Enorama Pharma AB upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 19, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Enorama Pharma AB as a current ratio of 0.25, with Debt / Equity ratio of 0.00%
- Current Ratio
- 0.25
- Quick Ratio
- 0.20
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.05
- Interest Coverage Ratio
- -4.91
Taxes
In the past 12 months, Enorama Pharma AB has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Enorama Pharma AB EV to EBITDA ratio is -0.99, with an EV/FCF ratio of -1.01.
- EV to Sales
- 37.18
- EV to EBITDA
- -0.99
- EV to Free Cash Flow
- -1.01
- EV to Operating Cash Flow
- -1.01
Balance Sheet
Enorama Pharma AB has SEK 2.10M in cash and marketable securities with SEK 0.00 in debt, giving a net cash position of SEK 2.10M billion.
- Cash & Marketable Securities
- SEK 2.10M
- Total Debt
- SEK 0.00
- Net Cash
- SEK 2.10M
- Net Cash Per Share
- SEK 0.03
- Tangible Book Value Per Share
- -SEK 0.68
Margins
Gross margin is -2955.18%, with operating margin of -3757.87%, and net profit margin of -4121.55%.
- Gross Margin
- -2955.18%
- Operating Margin
- -3757.87%
- Pretax Margin
- -4121.55%
- Net Profit Margin
- -4121.55%
- EBITDA Margin
- -3738.33%
- EBIT Margin
- -3763.26%
Analyst Forecast
The average price target for Enorama Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -87.19%
- EPS Growth Forecast
- 29.58%
Scores
- Smart Score
- ―
- AI Score
- 48
